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ABSTRACT
Objective To compare clinical and health economic 
outcomes after manubrium- limited mini- sternotomy 
(intervention) and conventional median sternotomy (usual 
care).
Design A single- blind, randomised controlled trial.
Setting Single centre UK National Health Service tertiary 
hospital.
Participants Adult patients undergoing aortic valve 
replacement (AVR) surgery.
Interventions Intervention was manubrium- limited 
mini- sternotomy performed using a 5–7 cm midline 
incision. Usual care was median sternotomy performed 
using a midline incision from the sternal notch to the 
xiphisternum.
Primary and secondary outcome measures The 
primary outcome was the proportion of patients who 
received a red cell transfusion postoperatively and within 
7 days of index surgery. Secondary outcomes included 
proportion of patients receiving a non- red cell blood 
component transfusion and number of units transfused 
within 7 days and during index hospital stay, quality of life 
and cost- effectiveness analyses.
Results 270 patients were randomised, received surgery 
and contributed to the intention to treat analysis. No 
difference between mini and conventional sternotomy 
in red- cell transfusion within 7 days was found; 23/135 
patients in each arm received a transfusion, OR 1.0 (95% 
CI 0.5 to 2.0) and risk difference 0.0 (95% CI −0.1 to 
0.1). Mini- sternotomy reduced chest drain losses (mean 
181.6 mL (SD 138.7) vs conventional, mean 306·9 mL 
(SD 348.6)); this did not reduce red- cell transfusions. 
Mean valve size and postoperative valve function were 
comparable between mini- sternotomy and conventional 
groups; 23 mm vs 24 mm and 6/134 moderate or severe 
aortic regurgitation vs 3/130, respectively. Mini- sternotomy 
resulted in longer bypass (82.7 min (SD 23.5) vs 59.6 min 
(SD 15.1)) and cross- clamp times (64.1 min (SD 17.1) 
vs 46·3 min (SD 10.7)). Conventional sternotomy was 
more cost- effective with only a 5.8% probability of mini- 
sternotomy being cost- effective at a willingness to pay of 
£20 000/QALY (Quality Adjusted Life Years).
Conclusions AVR via mini- sternotomy did not reduce 
red blood cell transfusion within 7 days following surgery 
when compared with conventional sternotomy.
Trial registration number ISRCTN29567910; Results.
OBJECTIVES
Aortic valve replacement (AVR) for severe 
symptomatic valvular disease is one of the 
most common cardiac surgical procedures 
performed worldwide. The current joint 
guidelines of the American College of Cardi-
ology and American Heart Association and 
the current European Society of Cardiology 
guidelines for the management of aortic 
valve disease state that surgical AVR is recom-
mended for symptomatic patients with severe 
aortic stenosis and asymptomatic patients 
with severe aortic stenosis who meet an indi-
cation for AVR when surgical risk is low or 
intermediate.1
In the UK, the National Adult Cardiac 
Surgery Audit published by National Institute 
for Cardiac Outcome Reporting reported 
13 027 procedures for aortic valve disease 
in the UK from April 2018 to March 2019.2 
Outcomes are generally excellent with in- hos-
pital observed mortality in the UK of 1.5% 
for first- time elective procedures.3 In low- risk 
patients with a EuroSCORE 2 of less than 4, 
a mortality of less than 0.7% was observed in 
over 15 000 patients undergoing AVR surgery 
in the UK between 2016 and 2019.2
Strengths and limitations of this study
 ► Large proportion of eligible patients recruited, and 
all patient randomised contributed to the primary 
outcome.
 ► Clear protocols for transfusion of blood and blood 
products with high adherence throughout the trial.
 ► Patients were blinded to group allocation until 2 
days following index surgery, reducing the likelihood 
of bias.
 ► First randomised trial to perform detailed health 
economic evaluation of minimally invasive versus 
conventional sternotomy.
 ► The trial was undertaken by three experienced min-
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These results are not observed in all patients; in high- 
risk groups, conventional surgery risks perioperative 
organ injury and prolonged recovery, with death in up to 
31% of patients within 1 year.4 Minimally invasive surgery 
combines the durability of surgical repair with reduc-
tions in surgical trauma that should reduce perioperative 
morbidity. Observational analyses demonstrating reduc-
tions in morbidity and resource use5 6 may be confounded 
by multiple sources of bias and are at odds with limited 
evidence from randomised controlled trials (RCTs) that 
have not shown improved outcomes.7 This uncertainty is 
reflected by variations in uptake internationally.8–10
The move towards minimally invasive surgery is also 
driven by patient perceptions of pain reduction and rapid 
recovery. However, minimally invasive cardiac surgery is 
not without risks; limiting access to the heart can result in 
technically suboptimal surgery, including concern about 
the size of the prosthesis that can be inserted and paraval-
vular leak rates.
This trial evaluated manubrium- limited mini- 
sternotomy versus conventional sternotomy for aortic 
valve replacement (MAVRIC). We hypothesised that 
mini- sternotomy would reduce red cell transfusion rates, 
a contemporary marker of surgical trauma and indicator 
of adverse outcomes11; this has been contested,12 though 
the evidence is not conclusive.13 An embedded cost- 
effectiveness analysis evaluated whether the intervention 




MAVRIC was a single- centre, single- blind, RCT comparing 
AVR via manubrium- limited mini- sternotomy group 
(intervention) and AVR via conventional sternotomy 
group (usual care). An NHS Research Ethics Committee 
approved the trial, which was conducted in accordance 
with the principles of the International Conference on 
Harmonisation of Good Clinical Practice.14 South Tees 
Hospitals NHS Foundation Trust was the sponsor and 
recruiting centre.
Patient and public involvement
In designing the study, we asked patients their view on 
what factors may affect whether they took part in the 
study. This was done in an outpatient setting and via a 
postal questionnaire. They felt expertise was important. 
Most patients felt that although the cosmetic benefit 
of the minimally invasive approach was appealing, they 
expected some clinical benefit from minimally inva-
sive surgery as well. Importantly, most patients said they 
would accept being blind to the type of surgery they had 
received for 48 hours after the procedure.
Participants
Patients were eligible if they were aged 18 years or over; 
required first- time, non- emergency, isolated AVR surgery 
and were willing to provide written informed consent. 
Full details of the eligibility criteria are in the online 
supplemental material.
Randomisation
Eligible patients were randomised by members of the 
research team using a 24- hour, central, secure, web- 
based randomisation system with concealed allocation, 
managed by the Clinical Trials Unit; randomisation was 
in a 1:1 ratio between mini and conventional sternotomy 
and stratified by baseline logistic EuroSCORE and preop-
erative haemoglobin (Hb).
Interventions
Manubrium- limited mini- sternotomy was performed 
using a 5–7 cm midline skin incision dividing the manu-
brium from the sternal notch to 1 cm below the manu-
brium–sternal junction. Cardiopulmonary bypass was 
established with an ascending aortic cannula and percuta-
neous femoral venous cannulation. Conventional median 
sternotomy was performed using a midline incision from 
the sternal notch to the xiphisternum. Key aspects of 
anaesthesia were standardised and are detailed in the 
protocol.15
Blinding
All patients were blinded to the type of sternotomy 
received until after their day 2 quality of life and pain 
assessments. All patients had trial- specific opaque dress-
ings applied to their sternal wound and groin before 
leaving theatre.
Transfusion protocol
The postoperative period, and trial protocol in relation to 
red cell and non- red cell transfusion, began on admission 
to the cardiothoracic intensive care unit; it specified that 
patients should receive a red cell transfusion if their Hb 
dropped below 80 g/L or were bleeding by 400 mL/hour 
or more, or were bleeding 100 mL/hour or more for 4 or 
more hours with an Hb equal to or greater than 80 g/L or 
had blood loss with haemodynamic instability irrespective 
of thromboelastography (TEG) and/or clotting profile 
results. One unit of red cells was transfused and Hb level 
checked before transfusing another unit.
Participants received a non- red cell transfusion if both 
of the following criteria were met: bleeding defined by 
400 mL/hour or more or blood loss of 100 mL/hour or 
more for 4 hours or more; TEG or coagulation- guided 
transfusion indicated.
Outcomes
All outcomes were measured from index surgery.
Primary outcome
The primary outcome was the proportion of patients who 
received a red cell transfusion postoperatively and within 
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Secondary outcomes
 ► Proportion of patients receiving a red cell transfusion 
and number of units transfused within 7 days and 
during index hospital stay.
 ► Proportion of patients receiving a non- red cell blood 
component transfusion and number of units trans-
fused within 7 days and during index hospital stay.
 ► Volume in chest drains at 6 and 12 hours and drain 
removal.
 ► Degree of aortic regurgitation using echocardiogram 
within 6 weeks.
 ► Re- operation rates.
 ► Conversion to conventional AVR during surgery.
 ► Changes in lung function at 4 days and 6 weeks.
 ► Quality of life EuroQol (EQ- 5D- 3L, EQ- VAS) at 2 days, 
6 and 12 weeks.
 ► Time patients are deemed ‘fit for discharge’.
 ► Healthcare utilisation to 12 weeks.
 ► Cost and cost- effectiveness analyses.
 ► Adverse events to 12 weeks.
Statistical analysis
Audit data had indicated 30% of patients undergoing AVR 
via conventional sternotomy (15 of 50 patients) received 
a red cell transfusion compared with 13% of patients (8 
of 60 patients) undergoing AVR via mini- sternotomy. 
Using Fisher’s exact test, 90% power, 5% alpha, we esti-
mated that 260 patients would be required to detect a 
17% reduction in the proportion of patients requiring a 
red cell transfusion (13% compared with 30%), using a 
two- sided test. Allowing for loss to follow- up, the sample 
size was increased to 270.
The primary analysis was based on intention- to- treat 
principles, in accordance with a pre- specified statistical 
analysis plan.
The primary efficacy analysis was based on a logistic 
regression model with only group (minimally invasive and 
conventional) and stratifying factors (baseline logistic 
EuroSCORE and Hb) as the predictors. ORs and their 
associated 95% CIs are reported in the primary analysis. 
Sensitivity analysis using alternating logistic regression 
was performed for the primary endpoint to sensitise for 
surgeon effects; the odds of receiving a red cell trans-
fusion for two patients treated by the same surgeon was 
compared with two patients treated by different surgeons.
All analyses of secondary continuous efficacy endpoints 
at single time points were based on linear models where, 
if appropriate, a log normal model was fitted to sensi-
tise the linearity assumption. Longitudinal analysis was 
performed for all endpoints with repeated data over time 
to investigate changes in trends over the trial period. The 
trial period was defined as baseline, up to 7 days (postop-
erative period), 6- week follow- up and 12- week follow- up. 
All analyses of binary endpoints at a single time point 
were based on logistic regression. Generalised estimating 
equation was used to analyse repeated binary data per 
patient to account for intrapatient correlation.
Further exploratory analysis was conducted to investigate 
the association between the treatment group and other 
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clinical factors. All analyses were performed using R V.3.3.3 
(The R Foundation) and SAS V.9.4 (SAS Institute).
Economic evaluation
A prospective economic evaluation applying an NHS 
perspective, following National Institute for Health and 
Care Excellence reference case guidance,16 was employed. 
Healthcare utilisation was captured up to 3 months 
following discharge from index surgery. Resource use was 
valued in 2016 pounds sterling using national sources,17 18 
and where necessary, local microcosting (£1=US$1.50). 
Resources included surgery, transfusions, length of 
hospital stay (by level of care), complications and further 
surgery and community care following discharge.
Mechanisms of missingness within the data were 
explored and multiple imputation methods were applied 
to impute missing data and minimise bias, using chained 
equations and predictive mean matching. Imputation 
sets were analysed within a bivariate analysis of costs and 
QALYs to generate incremental within- trial cost per QALY 
estimates and credible intervals. Findings were presented 
on the incremental cost- effectiveness ratio (ICER) plane 
and with cost- effectiveness acceptability curves, using the 
net monetary benefit approach.
Imputation was conducted according to good prac-
tice guidance.19 20 Multiple imputation provides unbi-
ased estimates of treatment effect if data are missing at 
random and the missingness process is adequately char-
acterised: this assumption was explored in the data, for 
example, by using logistic regression for missingness of 
costs and QALYs against baseline variables.21 A regres-
sion model was used to generate multiple imputed data-
sets (or ‘draws’) for individual treatment groups, where 
missing values were predicted drawing on predictive 
covariates. Outcome measures and costs (at each time 
point) contributed as predictors and imputed variables. 
Each draw provided a complete dataset, reflecting the 
distributions and correlations between variables. Predic-
tive mean matching drawn from the five nearest neigh-
bours (knn=5) was used to enhance the plausibility and 
robustness of imputed values; normality was not assumed. 
The imputation model used fully conditional (MCMC) 
methods. Draws were analysed using bivariate regression 
(see below) within the Stata MI framework, capturing 
within and between variances for imputed samples.22 
After examining the fraction of missing information from 




MAVRIC recruited to time and target; 313 patients were 
considered for the trial; 274 patients consented between 
20 March 2014 and 25 July 2016. The analysis population 
was 270 eligible patients; 135 allocated to the AVR via 
mini- sternotomy group and 135 allocated to the AVR via 
conventional sternotomy group (figure 1).
All 270 patients underwent surgery. Sixteen patients 
required cross- over from minimally invasive to a conven-
tional sternotomy due to anaesthetic emergency (n=2), 
difficulties due to vascular access (n=9) and intraopera-
tive complications (n=5); further details and the number 
of operations performed by surgeon are in the online 
supplemental material.
Baseline characteristics were similar between groups 
(table 1).
Primary outcome
There was no difference between groups in relation 
to the primary outcome (table 2). The proportion of 
patients receiving a red cell transfusion was 23 of 135 in 
both groups, OR 1.0 (95% CI 0.5 to 2.0; p=0.9052) and 
risk difference of 0.0 (95% CI −0.1 to 0.1; p=0.9999).
Secondary outcomes
Red cell and non-red cell transfusion
There was no significant difference between groups with 
respect to any red cell transfusion at discharge (table 2). 
There was no difference between groups in Hb from 
baseline to 4 days following index surgery (online supple-
mental material). There was a statistically significant 
difference in the proportion of patients receiving any 
non- red cell transfusion within 7 days of surgery; mini 
6/135 vs conventional 18/135, OR 0.3 (95% CI 0.1 to 0.8; 
p=00137) (table 3).
Cross-clamp time and cardiopulmonary bypass time
Mini- sternotomy resulted in longer cardio pulmonary 
bypass times; mini group 82.7 min (SD 23.5), conven-
tional 59.6 min (SD 15.1). Aortic cross- clamp times were 
also longer; mini group 64.1 min (SD 17.1), conventional 
46.3 min (SD 10.7) (table 4).
Chest drain losses
Mini- sternotomy resulted in a 40·8% reduction in chest 
drain losses at 12 hours, the mini group mean was 181.6 
mL (SD 138.7), conventional group mean was 306.9 mL 
(SD 348.6); the mean difference was −127.7 mL (95% CI 
−191.7 to –63.8, p=0.0001). At drain removal, mean differ-
ence was −145.3 mL (95% CI −218.1 to–72.3; p=0.0001) 
(table 4).
Ventilation time
Ventilation time between the groups was similar; 9·6 
hours (SD 5.6) in the mini group and 9.8 hours (SD 6.9) 
in the conventional (table 4).
Intensive care unit length of stay
There was no difference in intensive care unit length of 
stay between groups (online supplemental material).
Postoperative pain
There was no difference in pain scores between groups; 
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Lung function
There was no difference between groups in lung function 
at baseline. At 4 days post surgery, mean forced expira-
tory volume in 1 s (FEV1) 1123 mL (SD 433) and forced 
vital capacity (FVC) 1479 mL (SD 583) were significantly 
reduced in the mini group, compared with the conven-
tional; FEV1 1321 (SD 524), FVC 1698 (SD 707). Mean 
differences for FEV1 and FVC were statistically significant 
at 4 days post surgery; −171 mL (95% CI −265 to –77; 
p=0.0004) and −130 mL (95% CI −269 to 0; p=0.0498), 
respectively, after adjusting for baseline FEV1, FVC and 
randomisation factors (online supplemental material).
Hospital length of stay
The mean time to patients being fit for hospital discharge 
following index surgery was similar between groups. The 
mean postoperative hospital length of stay was 7.4 (SD 
7.5, range 3–79) in the mini group, and 6.3 days (SD 3.2, 
range 3–31) in the conventional (online supplemental 
material).
Postoperative valve function
The distribution of valve types and valve sizes by group was 
similar; mean valve size inserted was 23 mm in the mini 
group and 24 mm in the conventional (table 5, figures 2 
and 3). Over 70% of patients in each group received a 
tissue valve, over 25% received a mechanical valve and 
2%–3% received a sutureless tissue valve.
Postoperative transthoracic echo showed a similar 
decrease in mean aortic valve gradient in both groups 
to 16 mm Hg; peak gradient decreased to 30 mm Hg in 
both groups (table 5); 6/134 patients had moderate or 
severe aortic regurgitation in the mini group compared 
with 3/130 in the conventional (table 5). Only two 
patients in the trial, one in each arm, suffered a para-
valvular leak; both were severe. One of these patients, 
in the mini sternotomy arm, had a sutureless valve 
prosthesis. Seven further patients had moderate regur-
gitation; these were all intravalvular leaks. Transoesoph-
ageal echo was performed in all patients prior to leaving 
the operating theatre.
Adverse events
There were no in- hospital deaths in either group. At 
12 weeks follow- up, there were four deaths; two in each 
arm of the study. Adverse events in each group were 
broadly similar and within acceptable clinical limits. By 
12 weeks, 4/135 patients in the mini- sternotomy group 
and 1/135 in the conventional group had suffered a 
stroke (defined as a persistent neurological deficit). 
Atrial arrhythmias were identified in 61/135 patients in 
the mini group and 51/135 in the conventional. By 12 
weeks, 11/135 patients in the mini group and 3/135 
patients in the conventional had a sternal wound infec-
tion (online supplemental material).
Quality of life, costs and cost-effectiveness
Costs during the index admission were significantly greater for 
the mini group (mini- conventional: mean difference £1140; 
95% CI 303 to 1977), primarily reflecting the additional cost 
of theatre time (online supplemental material). Overall costs 
were not significantly different (mini- conventional: mean 
difference £746; 95% CI −245 to 1737). There was no signif-
icant difference in quality of life between groups up to 12 
weeks (mini- conventional: mean difference area under curve 
−0.009 QALYs; 95% CI 0.020 to 0.002). Although differences 








Baseline characteristics     
Age (years)     
  Mean±SD 69.3±9.3 68.7±8.4
  Range 43–85 39–88
Gender n (%)     
  Male 78 (57.8) 87 (64.4)
  Female 57 (42.2) 48 (35.6)
Ethnicity n (%)     
  White British 135 (100) 135 (100)
Body mass index (kg/m2)     
  Mean±SD 30.5±5.6 30.4±6.1
  Range (min–max) 19.0–45.4 19.3–52.0
EuroSCORE: Mean±SD 
(min–max)
    










    
  Regurgitation 3 (2.2) 8 (5.9)
  Stenosis 132 (97.8) 127 (94.1)
NYHA class: n (%)     
  I 24 (17.8) 18 (13.3)
  II 68 (50.4) 66 (48.9)
  III 40 (29.6) 46 (34.1)
  IV 3 (2.2) 5 (3.7)
*Haemoglobin prior to 
randomisation: g/dL
    
  Mean±SD 137.9±14.3 137.1±16.1
  Range (min–max) 97–173 90–175
Surgery type: n (%)     
  Elective 111 (82.2) 112 (82.6)
  In- house urgent 24 (17.8) 23 (17.4)
*One patient had a baseline haemoglobin (Hb) of 95 g/L at 
randomisation, which had fallen to 83 immediately prior to surgery. 
This Hb drop was not identified until after surgery and the patient 
continued in the trial with their data included in the analyses based 
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in costs and quality of life were not individually significant, 
the bivariate cost–QALY distribution (combining these two) 
suggests conventional surgery might be more cost- effective 
(figure 4). In the base- case model, mini was dominated by 
conventional surgery (due to greater cost and less benefit), 
with only a 5.8% probability of being cost- effective at a will-
ingness to pay of £20 000/QALY (table 6).
Sensitivity and subgroup analyses
There was no significant surgeon effect; the odds of 
receiving a red cell transfusion for two patients treated by 
the same surgeon compared with two patients treated by 
different surgeons was 1·2 (95% CI 0.9 to 1.6; p=0.1379).
Protocol deviations in respect of cell tranfusions did 
not affect the results of the primary analysis; excluding 
these patients produced the same results as those from 
the intention- to- treat analysis.
DISCUSSION
Main findings
Mini- sternotomy was not superior to conventional ster-
notomy with respect to red cell transfusion requirements 
within 7 days of surgery. Analysis of secondary endpoints 
showed a statistically significant difference in transfu-
sion volumes of non- red cell blood components. Aortic 
Table 2 The number and proportion of patients receiving a red cell transfusion*, and the number of units received, to 7 days 




sternotomy group OR (95% CI; p value)
Risk difference 
(95% CI; p value)
Red cell transfusions     
  Postoperatively to 7 days number of 
patients (%)
23/135 (17.0) 23/135 (17.0) 1.0 (0.5 to 2.0; 0.9052) 0.0 (−0.1 to 0.1; 
0.9999)
  Postoperatively to discharge number of 
patients (%)
34/135 (25.2) 29/135 (21.5) 1.4 (0.7 to 2.7)   
Red cell units—postoperatively to 7 days     
  Number of patients 23/135 23/135     
  Mean±SD 1.6±0.7 2.3±1.7     
  Range (min–max) 1–3 1–9     
Red cell units—postoperatively to discharge     
  Number of patients 34/135 29/135     
  Mean±SD 2.5±2.5 2.6±2.0     
  Range (min–max) 1–13 1–11     
*Reprinted from Hancock et al,28 with permission from Elsevier.
Table 3 The number and proportion of patients receiving a non- red cell transfusion, and the number of units received, to 7 




group OR (95% CI p value)
Non- red cell transfusions   
  Postoperatively to 7 days number of patients (%) 6/135 (4.4) 18/135 (13.3) 0.3 (0.1 to 0.8; 0.0137)
  Postoperatively to discharge number of patients (%) 13/135 (9.6) 21/135 (15.6) 0.6 (0.3 to 1.2)
Non- red cell component units—postoperatively to 7 days   
  Number of patients 6 18   
  Mean±SD 3.2±0.9 4.6±1.6   
  Range (min–max) 2–5 1–7   
Non- red blood cell units—postoperatively to discharge   
  Number of patients 13 21   
  Mean±SD 4.8±2.3 4.9±2.3   
  Range (min–max) 1–8 1–12   
Non- red cell component transfusions   
  Postoperatively to 7 days number of patients (%) 6 (4.4) 18 (13.3) 0.3 (0.1 to 0.8)
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valve size and postoperative function were comparable 
in the two groups. Mini- sternotomy resulted in a relative 
reduction in chest drain losses; however, higher blood 
loss in the conventional group did not translate into red 
cell transfusions. Mini patients had substantially longer 
bypass and cross- clamp times and worse lung function at 4 
days post surgery. Lung function at 12 weeks and adverse 
event rates were otherwise not different between groups. 
Conventional sternotomy was found to be more cost- 
effective. MAVRIC findings contradict those from other 
trials that pre- date it.23 24 Two 100 patient RCTs published 
since MAVRIC and the systematic review do not alter the 
discussion.25 26 Both found no difference in major clinical 
outcomes and findings relating to shorter hospital stay in 
mini- sternotomy; a reduction in bleeding through chest 
drains and mean difference in EQ- 5D scores at baseline 
and at 6 weeks25 are consistent with MAVRIC findings.
Strengths and limitations
This is the largest single trial to have compared minimally 
invasive sternotomy to conventional median sternotomy 
for AVR. A recent Cochrane review identified 511 patients 
from 7 previous RCTs.7 In MAVRIC, the mini- sternotomy 
technique divided only the manubrium and is therefore 
less invasive than other minimally invasive techniques. 
The trial was undertaken by three experienced minimally 
invasive surgeons who were expert at both techniques. 
Patients were blinded to group allocation until 2 days 
following index surgery, reducing the likelihood of bias. 
The trial recruited a significant proportion of eligible 
patients; 274/313 (86%), with few requiring conversion 
to conventional sternotomy, increasing the likelihood 
that the trial findings are generalisable. A further strength 
was the detailed health economic evaluation; this has not 
been performed previously.
The trial had some limitations, including the single 
centre design. This will tend to have biased treatment 
effect estimates away from the null, which is at odds with 
our observed effect. There were no significant levels of 
protocol non- adherence, with no effect on the main trial 
finding. The event rate for the primary outcome was much 
lower than expected at 17%; nationally red cell transfu-
sion rates following valve surgery are 46·4%.27 In our pre- 
trial audit conducted over 5 years, ending 2009, 30% of 
mini- sternotomy patients received a red cell transfusion. 
We attribute the observed transfusion rate in MAVRIC to 
the restrictive red cell transfusion threshold applied; this 
followed evidence at the time of trial design. The consul-
tant (expert) led nature of the trial interventions is also 
likely to have reduced the need for transfusions postop-
eratively and to have biased trial results towards the null.
Clinical importance
MAVRIC contributes important evidence to the minimally 
invasive AVR evidence base, summarised in a Cochrane 
review.7 MAVRIC demonstrated longer cross- clamp 
and bypass times with the manubrium- limited mini- 
sternotomy, attributed to known differences between the 
interventions. Minimally invasive techniques in MAVRIC 
required a number of surgical steps to be performed with 
the aortic clamp in place (drain insertion and pacing wire 
insertion, for example), meaning cross- clamp and bypass 
were longer. This is not an absolute requirement in other 
minimally invasive approaches; for example, where the 
incision is extended into the body of the sternum or 
where rapid deployment valves are used, there are no 
differences in cross- clamp and bypass times.7
The size of MAVRIC and event rate prevents formal 
comparison of adverse events between the groups, of note 
is the difference in stroke rate; this would benefit from 
exploration in a future trial.
The cost- effectiveness plane indicates that conventional 
surgery is less costly and more beneficial than minimally 
invasive surgery; contact with healthcare professionals 
was greater in the mini group, although there was no 
clear pattern of use. Wide CIs mean that differences are 






(95% CI; p value)
Cardio pulmonary bypass time (min)   
  Mean±SD 82.7±23.5 59.6±15.1   
  Range (min–max) 41.0–199 37.0–170.0   
Aortic cross- clamp time (min)   
  Mean±SD 64.1±17.1 46.3±10.7   
  Range (min–max) 32.0–132.0 32.0–97.0   
Drain losses at 12 hours   
  Mean±SD 181.6±138.7 306.9±348.6 −127.7 (−191.7 to –63.8; 0·0001)
  Range (min–max) 25–925 25–3000   
Drain losses at drain removal   
  Mean±SD 251.7±198.4 393.7±378.7 −145.3 (−218.1 to –72.3; 0·0001)
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imprecise. MAVRIC does not support the use of funds 
to expand AVR via manubrium- limited mini- sternotomy 
practice.
MAVRIC, the world’s largest RCT at low risk of bias, 
found no additional clinical benefit, in terms of red 
blood cell transfusion rates of minimally invasive AVR. 
Results are in agreement with the findings of a Cochrane 
review of trials that have evaluated mini- sternotomy AVR.7 
This information should be disseminated to patients, 
Table 5 Outcomes during index hospital stay for valve size 













(95% CI; p value)
Valve size: mm
  19–21 mm n (%) 40 (29.6) 38 (28.1)
  23–25 mm n (%) 84 (62.2) 80 (59.3)
  27–29 mm n (%) 11 (8.2) 17 (12.6)
  Mean±SD 23.1±2.1 23.6±2.5   
  Range (min–
max)
19.0–29.0 19.0–31.0   
  Valve type: n 
(%)
      
  Biological and 
sutureless
4 (3.0) 3 (2.2)   
  Biological 
prosthesis
96 (71.1) 98 (72.6)   
  Mechanical 
prosthesis
35 (25.9) 34 (25.2)   
Valve function       
Mean gradient       
Baseline       
  n 111* 110*   
  Mean±SD 47.9±15.7 47.7±20.2 0.2 (−4.6 to 5.0)
  Min–max 10–93 8–110   
6 weeks       
  n 120* 126*   
  Mean±SD 15.7±5.5 15.7±5.8 0.5†(−1.0 to 2.1)
  Min–max 6–33 4–34   
Peak gradient       
Baseline       
  n 125* 124*   
  Mean±SD 82.3±25.9 77.1±29.1 5.2 (−1.7 to 2.3)
  Min–max 16–152 8–173   
6 weeks       
  n 130* 130*   
  Mean±SD 29.9±10.5 29.7±10.8 −0.3† (−2.9 to 2.3)
  Min–max 12–62 11–61   
Aortic valve 
regurgitation
      
Nil/trivial       
  n/n (%) 109/134* 
(81.3)
109/130* (83.8) 218/264 (82.6)
Mild       
  n/n (%) 19/134* (14.2) 18/130* (13.9) 37/264 (14.0)
Moderate       
  n/n (%) 5/134* (3.7) 2/130* (1.5) 7/264 (2.7)
Severe       
  n/n (%) 1/134* (0.8) 1/130* (0.8) 2/264 (0.8)
*It was not possible to quantify valve function in all patients.
†After adjusting for randomisation factors and baseline data.
Figure 2 Valve size distribution: mini- sternotomy group.
Figure 3 Valve size distribution: conventional sternotomy 
group.
Figure 4 Cost- effectiveness plane, cost/QALY (£): mini- 
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clinicians and commissioners to inform decisions about 
AVR surgery including commissioning.
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